Arca
Skip to content
Tools
Tools

beta-thalassemia

Drug research and approvals for beta-thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 44 studies of beta-thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 4 approved and 10 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 44
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 4
  • EU medicines: 3

Recruiting now

Newest posted first, of 44 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 5

Phase 2 12 of 21

Phase 1 or earlier 11

How its trials ended

288 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 45 whose ending is known, 44% met their primary endpoint, 2% missed it and 53% stopped early.

  • Completed, result not reported10135%
  • Ongoing8931%
  • Status unknown5318%
  • Met its primary endpoint207%
  • Stopped: other or unclear93%
  • Stopped: enrollment or feasibility72%
  • Stopped: lack of efficacy41%
  • Stopped: sponsor or business decision41%
  • Missed its primary endpoint1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 13, 2019A phase 2a, randomized, open-label study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of isis 702843 administered…Isis 702843 (IONIS-TMPRSS6-LRX)Ionis PharmaceuticalsClosed
Jul 15, 2019A phase 1b sequential open label dose ranging study of safety, pharmacokinetics, and preliminary activity of benserazide in subjects with beta thalassemia…BenserazidePhoenicia Biosciences Inc.Pending
Mar 5, 2019A long-term follow-up study of subjects with beta-thalassemia or sickle cell disease treated with autologous CRISPR-CAS9 modified hematopoietic stem cells…CTX001 / Busulfan / PlerixaforVertex PharmaceuticalsOngoing
Feb 25, 2019A phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept(ACE-536) clinical trialsLuspatercept (ACE-536)Bristol-Myers SquibbOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jul 1, 2026CasgevyTreatment of patients aged 2 years and older with transfusion-dependent beta-thalassemia (TDT)Vertex Pharmaceuticals Inc.Approved
Dec 23, 2025AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemiaAgios Pharmaceuticals, Inc.Approved
Jan 16, 2024CasgevyTreatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT)Vertex Pharmaceuticals Inc.Approved
Aug 17, 2022ZyntegloTreatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusionsGenetix Biotherapeutics Inc.Approved
Nov 4, 2025DesidustatTreatment of beta-thalassemiaZydus Lifesciences LimitedDesignated
Jul 11, 2024Genetically modified CD34+ hematopoietic stem cells using a…Treatment of beta-thalassemiaKanglin Biotechnology (Hangzhou) Co., Ltd.Designated
Oct 15, 2020Synthetic 2?-O-(2-methoxyethyl)-modified antisense…Treatment of beta-thalassemiaIonis Pharmaceuticals, Inc.Designated
Jun 17, 20192-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluo…Treatment of beta-thalassemiaVifor Pharma, Inc.Designated
Jun 4, 2019Autologous CD34+ hematopoietic stem and progenitor cells…Treatment of beta-thalassemiaSangamo Therapeutics, Inc.Designated
Jun 21, 2016SirolimusTreatment of beta-thalassemia.Rare Partners srl Impresa SocialeDesignated
Jan 11, 2006Lentiviral vector encoded with a human beta-globin gene…Treatment of beta-thalassemia major and beta-thalassemia intermediaSan Rocco Therapeutics, LLCDesignated
Dec 21, 1998Deferoxamine starch conjugateTreatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.Biomedical Frontiers, Inc.Designated
Dec 18, 1992IsobutyramideTreatment of beta-hemoglobinopathies and beta-thalassemia syndromes.Perrine, Susan P., M.D.Designated
Apr 7, 1992Arginine butyrateTreatment of beta-hemoglobinopathies and beta-thalassemia.Perrine, Susan P., M.D.Designated

Medicines authorised in the EU

Newest first
Feb 9, 2024CasgevyExagamglogene autotemcel · orphanVertex Pharmaceuticals (Ireland) LimitedEMA ↗
Aug 28, 2006ExjadeDeferasiroxNovartis Europharm LimitedEMA ↗
Aug 25, 1999FerriproxDeferiproneChiesi Farmaceutici S.p.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.